Year All202420232022202120202019 Nov 28, 2023 Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement Nov 12, 2023 Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia Nov 07, 2023 Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results Oct 31, 2023 Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3 Oct 23, 2023 Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia Sep 26, 2023 Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023 Sep 21, 2023 Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference Sep 18, 2023 Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer Aug 10, 2023 Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results Aug 03, 2023 Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference
Nov 28, 2023 Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
Nov 12, 2023 Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia
Nov 07, 2023 Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
Oct 31, 2023 Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3
Oct 23, 2023 Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
Sep 26, 2023 Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023
Sep 18, 2023 Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer
Aug 10, 2023 Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results